Theranostic Imaging and Dosimetry for Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: closed (1 June 2024) | Viewed by 1685
Special Issue Editors
Interests: 177Lu-radioligand therapy; radioiodine-131 therapy; PET/CT; molecular imaging
Special Issue Information
Dear Colleagues,
It is our privilege to invite you to contribute to this Special Issue highlighting the role of theranostic imaging and dosimetry in oncologic treatments.
Today, a targeted approach in oncologic therapies seems hardly imaginable without the use of modern structural and molecular imaging modalities. The anatomically guided perspective of radiological diagnostics (CT and MRI) is broadened by the functional insight of nuclear medicine (SPECT and PET). These distinct perspectives may add up concordantly or be of complementary value in hybrid imaging (SPECT/CT, PET/CT, PET/MRI). Quantitative hybrid imaging is also a key to implementing dosimetric calculation in patients receiving radionuclide therapies, thus allowing for better patient selection, radiation safety, and personalized treatment approaches. An active dialog within the interrelated fields of radiology, nuclear medicine, and radiation therapy including experts in radiation physics is essential to further implement the emerging concept of "theranostics" and to optimize oncologic outcomes in treated patients.
Therefore, the aim of this Special Issue is to pinpoint and discuss newly established and recent approaches in radiology and nuclear medicine as well as associated fields of clinical and experimental research to refine cancer diagnostics, molecular therapies, and individualized dosimetry.
In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.
Dr. Christian Happel
Dr. Daniel Groener
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PET/CT
- SPECT/CT
- dosimetry
- radionuclide therapy
- radioembolization
- radioligand therapy
- nuclear medicine